GlaxoSmithKline Pharmaceuticals (500660) investor relations material

Executive summary

• Achieved strong revenue and profit growth in Q1 FY27, driven by portfolio transformation and execution excellence.

• Innovation portfolio contributed significantly to growth, with new launches in oncology and respiratory segments.

• Maintained leadership in key therapy areas and vaccines, with competitive performance from promoted brands.

• Unaudited standalone and consolidated financial results for the quarter ended 30th June 2026 were approved by the Board on 3rd August 2026.

• Board changes include the resignation of a Non-Executive Director, appointment of a new Non-Executive Director, and re-appointment of the Managing Director for two years from December 2026.

Financial highlights

• Standalone revenue from operations for Q1 FY27 was ₹92,442 lakhs, up from ₹80,483 lakhs year-over-year.

• EBITDA was ₹293 crore, up 17% year-over-year, with margin at 31.7% (+50 bps YoY).

• PAT stood at ₹253 crore, up 24% year-over-year, with margin at 27.6% (+200 bps YoY).

• Basic and diluted EPS for Q1 FY27 was ₹14.95, up from ₹12.08 year-over-year.

• Gross margin improved by 150 bps due to pricing and favorable mix.

Outlook and guidance

• Continued focus on innovation and accelerating R&D to drive future growth.

• Emphasis on simplifying operations and leveraging technology for agility.

• Upcoming launches in oncology, respiratory, and vaccines expected to sustain momentum.

• The company aims to double sales of its General Medicines growth engines by 2030 and reach over 1 billion patients this decade.